# Pro-urokinase for Extended-Window Posterior Circulation Stroke

Study · id `cardio:ct-nct07617870` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07617870](<https://clinicaltrials.gov/study/NCT07617870>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07617870

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 586 participants.

## Technical summary

Registry record NCT07617870. Randomized; quadruple masking; primary purpose treatment. Start 2026-06-01 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 586 participants (planned count; ClinicalTrials.gov record NCT07617870, source copy `cardio:ctgov-nct07617870-2026-06-01`, retrieved 2026-10-26)
- Planned start: 2026-06-01 (anticipated) (ClinicalTrials.gov record NCT07617870, source copy `cardio:ctgov-nct07617870-2026-06-01`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07617870, source copy `cardio:ctgov-nct07617870-2026-06-01`, retrieved 2026-10-26)
- Completion: 2028-06-30 (anticipated) (ClinicalTrials.gov record NCT07617870, source copy `cardio:ctgov-nct07617870-2026-06-01`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07617870, source copy `cardio:ctgov-nct07617870-2026-06-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07617870-2026-06-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pro-urokinase for Extended-Window Posterior Circulation Stroke
- Acronym: PROMISE
- Condition: Acute Ischemic Stroke
- Intervention (Drug): rhPro-UK
- Intervention (Drug): placebo
- Intervention (Drug): Aspirin
- Intervention (Drug): Placebo
- Lead sponsor: The First Affiliated Hospital of Zhengzhou University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital of Zhengzhou University (`cardio:org-the-first-affiliated-hospital-of-zhengzhou-university`)

## Provenance

Content hash: 766d75041a5d964fd83ee9f827954b7fc51dcebd2b8afa807ad6b3dd84f48011
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
